Terapiya nealkogol'noy zhirovoy bolezni pecheni. Est' li mesto dlya gepatoprotektorov?


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Currently, non-alcoholic fatty liver disease is the most common liver disease. Treatment of this disease includes the use of graduated exercises, diet modification, weight reduction, the use of insulin sensitizers, and drugs with cytoprotective activity, including essential phospholipids and antioxidants. The article analyzes the current data on the pathogenesis, risk factors and principles of treatment of non-alcoholic fatty liver disease (NAFLD). Methods of treatment of NAFLD develop rapidly, and it requires medical attention.

Толық мәтін

Рұқсат жабық

Әдебиет тізімі

  1. Цуканов В.В, Тонких Ю.Л, Каспаров Э.В. и др. Неалкогольная жировая болезнь печени у взрослого городского населения России (распространенность и факторы риска). Врач. 2010;9:2-6.
  2. Schuppan D., Schattenberg J.M. Nonalcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J. Gastroenterol. Hepatol. 2013;28(Suppl. 1): 68-76.
  3. Verbeek J., Cassiman D., Lannoo M., et al. Treatment of non-alcoholic fatty liver disease: can we already face the epidemic? Acta. Gastroenterol. Belg. 2013;76(2): 200-09.
  4. Цуканов В.В., Ноздрачев К.Г., Тонких Ю.Л. Метаболические факторы защиты коренного населения Севера при ИБС и холелитиазе. Бюлл. СО РАМН. 2006;2:100-04.
  5. Цуканов В.В., Селиверстова Е.В., Догадин С.А. сахарным диабетом. Терапевтический архив. 2005;77(2):15-8.
  6. Цуканов В.В., Тонких Ю.Л., Бронникова Е.П. Механизм нормолипидемии у северных народностей. Клин. медицина. 1999; 2:38-42.
  7. Sookoian S., Pirola C.J. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011 ;53(6):1883-94.
  8. Romeo S., Kozlitina J., Xing C., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008;40(12):1461-65.
  9. Speliotes E.K., Yerges-Armstrong L.M., Wu J. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011;7(3):e1001324.
  10. Krawczyk M., Portincasa P., Lammert F. PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease. Semin. Liver Dis. 2013;33(4):369-79.
  11. Anstee Q.M., Day C.P. The genetics of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2013;10(11 ):645-55.
  12. Eckard C., Cole R., Lockwood J., et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therap. Adv. Gastroenterol. 2013;6(4):249-59.
  13. Tomeno W., Yoneda M., Imajo K., et al. Emerging drugs for non-alcoholic steatohepatitis. Expert Opin. Emerg. Drugs. 2013;18(3):279-90.
  14. de Wit N.J., Afman L.A., Mensink M., et al. Phenotyping the effect of diet on nonalcoholic fatty liver disease. J. Hepatol. 2012;57(6):1370-73.
  15. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592-609.
  16. Belfort R., Harrison S.A., Brown K., et al. A placebo controlled trial of pioglitazone in subjects with non-alcoholic steatohepatitis. N. Engl. J. Med. 2006;355(22):2297-307.
  17. Rakoski M.O., Singal A.G., Rogers M.A., et al. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2010;32( 10):1211-21.
  18. Ивашкин В.Т., Маевская М.В. Липотоксичность и метаболические нарушения при ожирении. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2012;1:82-6.
  19. Nascimbeni F., Pais R., Bellentani S. et al. From NAFLD in clinical practice to answers from guidelines. J. Hepatol. 2013;59(4):859-71.
  20. Jacobs R.L., van der Veen J.N., Vance D.E. Finding the balance: the role of S-adenosylmethionine and phosphatidylcholine metabolism in development of nonalcoholic fatty liver disease. Hepatology. 2013;58(4):1207-209.
  21. Anstee Q.M., Day C.P. A lipid to treat non-alcoholic fatty liver disease - the dawn of 'lipo-rehabilitation'7 J. Hepatol. 2012;56(4):987-89.
  22. Xiang Z., Chen Y.P., Ma K.F. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol. 2013;13(9):140-52.
  23. Pathil A., Mueller J., Warth A., et al. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology. 2012;55(5):1369-78.
  24. Andreone P., Brisc M.C., Chiaramonte M., et al. Silybin conjugated with phosphatidilcholine and vitamin E improves liver damage in patients with NAFLD: the results of a randomized multicentre doubleblind vs. placebo trial. J. Hepatol. 2011; 54(Suppl. P):S330-31.
  25. Sas E., Grinevich V., Efimov O., et al. Beneficial influence of polyunsaturated phosphatidylcholine enhances functional liver condition and liver structure in patients with nonalcoholic steatohepatitis. Results of prolonged randomized blinded prospective clinical study. J. Hepatology. 2013; 58(Suppl. 1):S549.
  26. Lomonaco R., Sunny N.E., Bril F. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs. 2013;73(1):1-14.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2014

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>